<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932321</url>
  </required_header>
  <id_info>
    <org_study_id>PR-03903</org_study_id>
    <nct_id>NCT00932321</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of an Oral Contraceptive</brief_title>
  <official_title>Open Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate (NA) and Ethinyl Estradiol (EE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative study. The primary objective of the study is to assess the efficacy of
      a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to
      assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol
      (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the
      safety and tolerability of the product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population</measure>
    <time_frame>5.6 months (6 - 28 day cycles)</time_frame>
    <description>Pearl Index = 1300 * number of pregnancies/number of women-cycles of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population</measure>
    <time_frame>5.6 months (6 - 28 day cycles)</time_frame>
    <description>Self-reported via patient completed diary (none - no vaginal bleeding, light - less than normal menstruation, normal - like normal menstruation, heavy - more than normal menstruation) along with daily use of sanitary protection (other than panty liners). Light bleeding requiring no more than single pad or tampon will be spotting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">938</enrollment>
  <condition>Prevention of Pregnancy</condition>
  <arm_group>
    <arm_group_label>24 Day NA/EE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>21 Day NA/EE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone Acetate/Ethinyl Estradiol 24 Days</intervention_name>
    <description>One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets</description>
    <arm_group_label>24 Day NA/EE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norethindrone Acetate /Ethinyl Estradiol 21 Days</intervention_name>
    <description>One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets</description>
    <arm_group_label>21 Day NA/EE</arm_group_label>
    <other_name>21 Day NA/EE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Women

          -  Age 18-45

          -  At risk for pregnancy

          -  History of regular cycles

        Exclusion Criteria:

          -  Contraindications for use of hormonal contraception

          -  Conditions which affect the absorption or metabolism of steroid hormones

          -  BMI &gt; 35
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herman Ellman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Chico</city>
        <state>California</state>
        <zip>95929</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34285</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Powder Springs</city>
        <state>Georgia</state>
        <zip>30127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <results_first_submitted>February 22, 2011</results_first_submitted>
  <results_first_submitted_qc>February 22, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2011</results_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>32 investigational study sites recruited 938 women aged 18 - 45 years of age beginning Feb '04</recruitment_details>
      <pre_assignment_details>MITT Population defined as subset of All Treated Subjects who were evaluated for pregnancy, either positive or negative, at least once after beginning the study medication. Completed subjects - subset of MITT subjects completing at least 161 days of treatment based on returned drug or diary.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>24 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 24 days followed by 4 placebo tablets</description>
        </group>
        <group group_id="P2">
          <title>21 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 21 days followed by 7 placebo tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="751"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MITT Population</title>
              <participants_list>
                <participants group_id="P1" count="705"/>
                <participants group_id="P2" count="181"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="580"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>24 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 24 days followed by 4 placebo tablets</description>
        </group>
        <group group_id="B2">
          <title>21 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 21 days followed by 7 placebo tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="751"/>
            <count group_id="B2" value="187"/>
            <count group_id="B3" value="938"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>MITT (Modified Intent to Treat) Population</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age, Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="579"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="751"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="751"/>
                    <measurement group_id="B2" value="187"/>
                    <measurement group_id="B3" value="938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population</title>
        <description>Pearl Index = 1300 * number of pregnancies/number of women-cycles of treatment</description>
        <time_frame>5.6 months (6 - 28 day cycles)</time_frame>
        <population>Modified intention to treat (MITT) subset of all treat subjects - evaluated for pregnancy at least once after beginning study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>24 Day NA/EE</title>
            <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 24 days followed by 4 placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>21 Day NA/EE</title>
            <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 21 days followed by 7 placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population</title>
          <description>Pearl Index = 1300 * number of pregnancies/number of women-cycles of treatment</description>
          <population>Modified intention to treat (MITT) subset of all treat subjects - evaluated for pregnancy at least once after beginning study medication.</population>
          <units>Pearl Index</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="705"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.823"/>
                    <measurement group_id="O2" value="2.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population</title>
        <description>Self-reported via patient completed diary (none - no vaginal bleeding, light - less than normal menstruation, normal - like normal menstruation, heavy - more than normal menstruation) along with daily use of sanitary protection (other than panty liners). Light bleeding requiring no more than single pad or tampon will be spotting.</description>
        <time_frame>5.6 months (6 - 28 day cycles)</time_frame>
        <population>Modified Intent to Treat (MITT)</population>
        <group_list>
          <group group_id="O1">
            <title>24 Day NA/EE</title>
            <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 24 days followed by 4 placebo tablets</description>
          </group>
          <group group_id="O2">
            <title>21 Day NA/EE</title>
            <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 21 days followed by 7 placebo tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Intracyclic Bleeding (IB)/Spotting Days in Cycles 2-6, MITT Population</title>
          <description>Self-reported via patient completed diary (none - no vaginal bleeding, light - less than normal menstruation, normal - like normal menstruation, heavy - more than normal menstruation) along with daily use of sanitary protection (other than panty liners). Light bleeding requiring no more than single pad or tampon will be spotting.</description>
          <population>Modified Intent to Treat (MITT)</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="705"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="9.16"/>
                    <measurement group_id="O2" value="7.31" spread="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Primary hypothesis tested was the independence (lack of association) of mean number of IB days in Cycles 2-6 across treatment groups.</non_inferiority_desc>
            <p_value>0.311</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratified by investigational site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months, between 5 Feb 2004 and 30 Nov 2004</time_frame>
      <desc>Nine randomized subjects returned all study medication unused resulting in the following treated subjects: 743 in 24 day NA/EE group and 186 in 21 day NA/EE group. Adverse Events were collected on this population.</desc>
      <group_list>
        <group group_id="E1">
          <title>24 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 24 days followed by 4 placebo tablets</description>
        </group>
        <group group_id="E2">
          <title>21 Day NA/EE</title>
          <description>Norethindrone acetate/ethinyl estradiol 1 tablet daily for 21 days followed by 7 placebo tablets</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Partial Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="457" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Viral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear Cervix Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Metorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="186"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Grexan Wulff, Manager Regulatory Affairs</name_or_title>
      <organization>Warner Chilcott</organization>
      <phone>973-442-3376</phone>
      <email>gwulff@wcrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

